A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasms|Neoplasms, Ovarian|Neoplasms, Breast|Advanced or Refractory Solid Malignancies
Interventions: DRUG: DOXIL/CAELYX (doxorubicin) Treatment Sequence AB|DRUG: DOXIL/CAELYX (doxorubicin) Treatment Sequence BA
Sponsor: Janssen Research & Development, LLC